You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Philadelphia Negative Myeloproliferative Tumors Trial

Not yet recruiting
  • Philadelphia Negative Myeloproliferative Neoplasms
    • (no location specified)
    Jun 5, 2022

    Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Worldwide

    Recruiting
    • Primary Myelofibrosis
    • +2 more
    • Birmingham, Alabama
    • +151 more
    Aug 22, 2022

    Myeloproliferative Disorder, Myeloproliferative Syndrome, Myelofibrosis Trial in Irvine (USDA Diet, Mediterranean Diet)

    Completed
    • Myeloproliferative Disorder
    • +4 more
    • USDA Diet
    • Mediterranean Diet
    • Irvine, California
      University of California, Irvine
    Mar 23, 2020

    Myeloproliferative Tumor, Polycythemia Vera, Essential Thrombocythemia Trial in Hong Kong

    Recruiting
    • Myeloproliferative Neoplasm
    • +7 more
      • Hong Kong, Hong Kong
        Department of Medicine, Queen Mary Hospital
      May 21, 2023

      Epigenetic Age on Clinic-biological Presentation and Prognosis

      Not yet recruiting
      • Myeloproliferative Neoplasm
      • Assessment of the epigenetic age
      • Bordeaux, France
        CHU de Bordeaux, service Hématologie Biologique
      Aug 28, 2023

      Ruxolitinib in Patients With Myelofibrosis

      Not yet recruiting
      • Myelofibrosis
      • (no location specified)
      Feb 28, 2023

      Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Ipoh (NS-018,

      Recruiting
      • Primary Myelofibrosis
      • +2 more
      • Worcester, Massachusetts
      • +16 more
      Oct 31, 2022

      Myelofibrosis, Polycythemia Vera Trial in United States (TGR-1202, ruxolitinib)

      Active, not recruiting
      • Myelofibrosis
      • Polycythemia Vera
      • Phoenix, Arizona
      • +4 more
      Jun 20, 2022

      Thrombosis in Myeloproliferative Neoplasms

      Completed
      • Myeloproliferative Neoplasm
      • 2 additional tubes of blood
      • Angers, France
      • +23 more
      Aug 17, 2022

      Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis Trial in United States

      Completed
      Has Results
      • Primary Myelofibrosis
      • +2 more
      • Scottsdale, Arizona
      • +8 more
      Feb 10, 2022

      Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis Trial in Worldwide

      Completed
      Has Results
      • Primary Myelofibrosis
      • +2 more
      • Phoenix, Arizona
      • +61 more
      May 5, 2022

      Myelofibrosis Trial (Momelotinib)

      Available
      • Myelofibrosis
      • (no location specified)
      Oct 12, 2022

      Myelofibrosis Due to and Following Polycythemia Vera Trial in United States (Ruxolitinib, Abemaciclib)

      Recruiting
      • Myelofibrosis Due to and Following Polycythemia Vera
      • Basking Ridge, New Jersey
      • +6 more
      Jan 26, 2023

      Assess the Safety of Fedratinib in Korean Myelofibrosis

      Recruiting
      • Primary Myelofibrosis
      • +2 more
      • Seoul, Korea, Republic of
        Bristol-Myers Squibb YH
      Oct 3, 2023

      Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera

      Completed
      • Adherence, Patient
      • Adherence, Treatment
        • Cosenza, Calabria, Italy
        • +27 more
        Oct 11, 2023

        Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)

        Not yet recruiting
        • Myelofibrosis (PMF)
        • +2 more
        • New York, New York
          Ruttenberg Treatment Center
        Apr 18, 2023

        Real World Evidence of Fedratinib Effectiveness in MF

        Not yet recruiting
        • Primary Myelofibrosis
        • +2 more
        • (no location specified)
        May 22, 2023

        Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid

        Active, not recruiting
        • Acute Myeloid Leukemia
        • +9 more
        • Los Angeles, California
        • +5 more
        Jan 27, 2023

        Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis Trial in Houston

        Completed
        • Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
        • +2 more
        • Laboratory Biomarker Analysis
        • +2 more
        • Houston, Texas
          M D Anderson Cancer Center
        May 27, 2022

        Myelofibrosis Trial in Houston (CK0804)

        Not yet recruiting
        • Myelofibrosis
        • Houston, Texas
          The University of Texas MD Anderson Cancer Center
        Jun 28, 2022

        Myeloproliferative Neoplasms (MPN) and COVID-19

        Recruiting
        • Myeloproliferative Neoplasm
        • COVID
          • New York, New York
          • +43 more
          Apr 4, 2022

          Myeloproliferative Neoplasia With Normal CBC and Thrombotic

          Recruiting
          • Thrombotic Patients
          • +2 more
            • Nantes, Loire-Atlantique, France
              Nantes University Hospital
            Sep 8, 2021

            Myelofibrosis Trial in Worldwide (PXS-5505)

            Recruiting
            • Myelofibrosis
            • Birmingham, Alabama
            • +19 more
            Nov 28, 2022

            Polycythemia Vera Trial (Givinostat Hydrochloride, Hydroxy Urea)

            Not yet recruiting
            • Polycythemia Vera
            • Givinostat Hydrochloride
            • Hydroxy Urea
            • (no location specified)
            Oct 19, 2023

            Acute Myeloid Leukemia, Myeloproliferative Syndrome Trial in France (CPX-351)

            Not yet recruiting
            • Acute Myeloid Leukemia
            • Myeloproliferative Syndrome
            • Amiens, France
            • +33 more
            Feb 7, 2022